We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAPR icon
201
Capricor Therapeutics
CAPR
$380M
$1.3M 0.05%
+25,840
New +$1.62M
ZSAN
202
DELISTED
Zosano Pharma Corporation
ZSAN
$1.26M 0.05%
247
+45
+22% +$278K
ORMP icon
203
Oramed Pharmaceuticals
ORMP
$167M
$1.2M 0.04%
+212,017
New +$1.45M
ALBO
204
DELISTED
Albireo Pharma Inc
ALBO
$1.18M 0.04%
38,313
+31,063
+428% +$1.04M
TSRO
205
PUT
DELISTED
TESARO, Inc.
TSRO
$1.18M 0.04%
+200
New +$11.5K
RXII
206
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$1.16M 0.04%
6,832
+60
+0.9% +$10.2K
NBIX icon
207
PUT
Neurocrine Biosciences
NBIX
$18.4B
$1.15M 0.04%
241
– –
MBOT icon
208
Microbot Medical
MBOT
$115M
$1.14M 0.04%
1,307
-1,570
-55% -$1.85M
CTIC
209
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.12M 0.04%
575
– –
SGYPW
210
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$1.11M 0.04%
296,606
-108,021
-27% -$189K
VIVS
211
VivoSim Labs
VIVS
$1.21M
$1.09M 0.04%
+1,207
New +$1.35M
LAB icon
212
CALL
Standard BioTools
LAB
$357M
$1.08M 0.04%
+445
New +$14K
QURE icon
213
CALL
uniQure
QURE
$2.78B
$1.03M 0.04%
+382
New +$10.9K
LRMR icon
214
PUT
Larimar Therapeutics
LRMR
$387M
$1.02M 0.04%
+25
New +$10.5K
ETRM
215
DELISTED
EnteroMedics Inc.
ETRM
$1.02M 0.04%
+1,572
New +$1.81M
PLUR icon
216
PUT
Pluri
PLUR
$17M
$996K 0.04%
49
+6
+14% +$1.32K
INSM icon
217
PUT
Insmed
INSM
$22.7B
$974K 0.04%
+399
New +$9.06K
FOLD
218
CALL
DELISTED
Amicus Therapeutics
FOLD
$896K 0.03%
633
-1,151
-65% -$13.8K
OMER icon
219
CALL
Omeros
OMER
$852M
$894K 0.03%
497
-1,531
-75% -$33K
LSTA icon
220
Lisata Therapeutics
LSTA
$10.3M
$889K 0.03%
+3,169
New +$1.18M
CHRS icon
221
Coherus Oncology
CHRS
$221M
$867K 0.03%
+30,000
New +$758K
EXEL icon
222
CALL
Exelixis
EXEL
$14.1B
$856K 0.03%
2,276
-2,043
-47% -$6.64K
MNKD icon
223
MannKind Corp
MNKD
$1.21B
$838K 0.03%
29,461
-223,229
-88% -$5.7M
ABEO icon
224
Abeona Therapeutics
ABEO
$355M
$808K 0.03%
6,390
-25,124
-80% -$3.77M
INSM icon
225
CALL
Insmed
INSM
$22.7B
$796K 0.03%
326
– –
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.